TD Cowen lowered the firm’s price target on Standard BioTools to $2.75 from $3.50 and keeps a Buy rating on the shares. The firm noted they posted a 2Q miss, a material 2024 guide cut, and a CFO departure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Standard BioTools CFO Resigns, COO Steps in Interim
- Standard BioTools Forecasts Revenue Outlook for 2024
- Standard BioTools Announces Senior Leadership Changes
- LAB Earnings this Week: How Will it Perform?
- Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024